Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The diphtheria, tetanus, and poliomyelitis vaccine (Td/IPV) is a trivalent biological product used for active immunization against three infectious diseases: diphtheria, tetanus, and poliomyelitis. It contains inactivated diphtheria and tetanus toxoids along with inactivated poliovirus (IPV) types 1, 2, and 3. The vaccine is typically administered as a booster dose in adolescents and adults to maintain immunity acquired during childhood. It works by inducing the immune system to produce specific antitoxins and neutralizing antibodies. Common brand names include REVAXIS, while versions containing additional components like pertussis (Tdap-IPV) include Adacel-Polio and Boostrix-Polio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphtheria, tetanus, and poliomyelitis vaccine.